Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sits in the top decile of US sponsors by registered trial count (#69 of 15,742 sponsors by registered trial count).
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: 523 sponsored US clinical trials, 69 recruiting.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsors 523 registered US clinical trials on ClinicalTrials.gov, 69 of them currently recruiting, and 301 completed. 5 of these trials are in Phase 3-4 (later-stage) and 395 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 17 trials.
Top-decile sponsor footprint
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ranks in the top decile of sponsors by registered trial count (#69 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
301 of 415 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
523 total, page 2 of 11
Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma
NCT05141513
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT04704505
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
NCT05013216
Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell
NCT07062549
Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca
NCT04988074
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
NCT04753879
Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer
NCT04892303
HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
NCT04131413
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
NCT04363164
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
NCT04248569
Proton Radiation Therapy Registry
NCT04376229
Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures
NCT04232085
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
NCT03786796
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
NCT03521830
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
NCT03465592
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
NCT03223922
Image-Guided Gynecologic Brachytherapy
NCT02993900
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
NCT05995821
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
NCT01804634
Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML
NCT05716009
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
NCT05823571
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
NCT05014776
Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors
NCT05121545
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
NCT04658147
Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca
NCT04848116
Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
NCT04447651
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
NCT04209686
Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer
NCT04386746
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
NCT04117087
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
NCT03961971
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
NCT03918252
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
NCT03875287
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
NCT03610711
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
NCT03607890
Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
NCT03573648
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
NCT03439735
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
NCT03471650
Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins
NCT02965755
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
NCT03114865
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
NCT03044613
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT02845323
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
NCT02989636
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
NCT03047135
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
NCT02923180
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
NCT02738866
Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer
NCT02743910
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
NCT02452008
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
NCT02451982
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
NCT02259621
Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme
NCT02177578
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 185 |
| Phase 2 | 210 |
| Phase 3 | 5 |
Therapeutic Areas
What is open in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins pipeline
69 recruiting of 523 indexed (13% open); 301 completed (58%).
Phase mix: 5 late (III/IV) vs 395 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: open-pipeline peers nationwide
Peers matched on 523 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 523 trials (± recruiting share)
- AbbVie · 526 trials · 21% recruiting
- Boehringer Ingelheim · 515 trials · 8% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 13% open enrollment (± trial volume)
- MetroHealth Medical Center · 13% recruiting · 76 trials
- Texas Tech University Health Sciences Center · 13% recruiting · 76 trials
- Chiesi Farmaceutici S.p.A. · 13% recruiting · 30 trials
- Dizal Pharmaceuticals · 13% recruiting · 15 trials
Related
What to do with this Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins page
523 registered trials is a research-attention snapshot, not an endorsement of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins or any single study.
- 69 of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins pipeline card: 523 registered trials from official public datasets.Report a data error.